Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHA) EPS (Basic) (2018 - 2025)

Historic EPS (Basic) for Innate Pharma (IPHA) over the last 8 years, with Q2 2025 value amounting to -$90496.0.

  • Innate Pharma's EPS (Basic) fell 1569.04% to -$90496.0 in Q2 2025 from the same period last year, while for Jun 2025 it was -$90496.0, marking a year-over-year decrease of 1569.04%. This contributed to the annual value of -$0.11 for FY2024, which is 1255.46% down from last year.
  • Innate Pharma's EPS (Basic) amounted to -$90496.0 in Q2 2025, which was down 1569.04% from -$0.67 recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's EPS (Basic) registered a high of $28400.0 during Q2 2023, and its lowest value of -$90496.0 during Q2 2025.
  • Its 5-year average for EPS (Basic) is -$13378.3, with a median of -$0.72 in 2023.
  • In the last 5 years, Innate Pharma's EPS (Basic) surged by 321232.88% in 2023 and then tumbled by 37543.16% in 2024.
  • Over the past 5 years, Innate Pharma's EPS (Basic) (Quarter) stood at -$1.44 in 2021, then skyrocketed by 52.88% to -$0.68 in 2022, then fell by 5.36% to -$0.72 in 2023, then rose by 6.43% to -$0.67 in 2024, then plummeted by 13500510.7% to -$90496.0 in 2025.
  • Its EPS (Basic) stands at -$90496.0 for Q2 2025, versus -$0.67 for Q4 2024 and -$78222.6 for Q2 2024.